Obstructive Sleep Apnea — ENT Perspective

• Upper airway collapse mechanism: During wakefulness, the pharyngeal airway maintains patency through active muscle contraction mediated by the hypoglossal nerve (CN XII) and vagal innervation. Sleep causes a physiologic reduction in muscle tone, but in OSA patients, this reduction is exaggerated due to either intrinsic neuromuscular dysfunction or the interaction between reduced tone and severe anatomic narrowing. The critical closing pressure (Pcrit)—the pressure at which the airway collapses—is elevated in OSA patients. When intrapharyngeal pressure during inspiration becomes more negative than Pcrit, the airway completely occludes despite respiratory effort, creating an obstructive apnea event. Each obstructive event lasts 10-120 seconds and terminates only when arousal from sleep occurs, restoring neuromuscular tone and airway patency. This cycle of obstruction, hypoxemia/hypercapnia, and arousal repeats throughout the night.

• Airway anatomic abnormalities: Multiple anatomic factors reduce pharyngeal cross-sectional area, including retrognathia or micrognathia (posteriorly positioned or undersized mandible), maxillary hypoplasia, tonsillar hypertrophy, adenoid enlargement (particularly in pediatric OSA), soft palate elongation, palatal vault narrowing, lateral pharyngeal wall collapse, lingual tonsil hypertrophy, and epiglottic abnormalities. The Mallampati classification (modified to account for tonsillar size) correlates with airway narrowing; Mallampati 3-4 (palate obscured by tonsillar enlargement) predicts increased OSA risk. Obesity contributes through multiple mechanisms: increased soft tissue mass in the neck, altered fat distribution in the pharyngeal walls (demonstrated on CT/MRI as increased parapharyngeal fat), reduced lung volumes with increased closing pressures, and potentially decreased arousal threshold.

• Sleep stage-dependent physiology: REM sleep produces physiologic atonia of skeletal muscles except the diaphragm, creating maximum vulnerability to airway collapse. Non-REM sleep, particularly stage N2 and N3, also reduces pharyngeal tone but less dramatically than REM. The transition between sleep stages and the cyclic alternating pattern (CAP) in light sleep contribute to variability in obstruction severity. Supine sleep position dramatically increases airway collapse frequency because gravity worsens the retrograde motion of the tongue and soft palate, explaining why positional therapy improves some patients' OSA.

• Arousal response and sleep fragmentation: Obstructive events trigger increasingly negative intrapharyngeal pressures (up to -60 cm H₂O) and associated hypoxemia and hypercapnia. Chemoreceptors (peripheral and central) and mechanoreceptors sensing airway occlusion trigger cortical arousal via the ascending reticular activating system. The arousal response—lasting 3-15 seconds—restores consciousness and muscle tone, reopening the airway and allowing ventilation, but interrupts sleep architecture. This repetitive cycle (sleep→collapse→hypoxemia→arousal→brief awakening→return to sleep→collapse) fragments sleep architecture, reducing slow-wave sleep (N3) and REM sleep in favor of light sleep (N1-N2), resulting in nonrestorative sleep and excessive daytime somnolence (EDS).

• Oxygen desaturation cascade: During apneic events, alveolar oxygen tension falls due to continued oxygen consumption without ventilation. The baseline oxygen saturation, duration of apnea, and functional residual capacity (lower in obese patients) determine the magnitude of desaturation. In severe OSA, oxygen saturation may fall from 95% to 70% or lower, with some patients experiencing periodic breathing patterns (Cheyne-Stokes respirations superimposed on obstructive events). These recurrent hypoxic episodes activate inflammatory pathways, including hypoxia-inducible factor (HIF-1α), NF-κB signaling, and production of reactive oxygen species (ROS). Intermittent hypoxia paradoxically activates more severe systemic inflammatory responses than sustained hypoxia, contributing to cardiovascular complications.

• Systemic inflammatory and sympathomimetic consequences: Repetitive arousals and hypoxic episodes activate the sympathetic nervous system, increasing circulating catecholamines, angiotensin II, and inflammatory cytokines (TNF-α, IL-6, C-reactive protein). These changes increase blood pressure, promote atherosclerosis, increase platelet aggregability, and enhance thrombotic potential. Endothelial dysfunction develops through reduced nitric oxide availability and increased oxidative stress, contributing to hypertension and vascular disease. The intermittent nature of hypoxia appears more harmful than sustained hypoxia, explaining why OSA patients have disproportionate cardiovascular risk compared to patients with comparable chronic hypoxemia from other causes.

• Anatomic airway narrowing (primary ENT contributor): Structural abnormalities reduce pharyngeal cross-sectional area and include tonsillar hypertrophy (common in children and some adults), adenoid enlargement, soft palate elongation, deviated septum (though septum is nasal rather than pharyngeal), septal hypertrophy, lingual tonsil hypertrophy, pharyngeal web formation, epiglottic abnormalities, and laryngomalacia (in infants). Retrognathia, micrognathia, and maxillary hypoplasia create skeletal constraints on airway space. High-arched palate and narrow hard palate width also predispose. These anatomic factors are more prevalent in certain populations: micrognathia occurs in Down syndrome, Pierre Robin sequence, and achondroplasia; tonsillar hypertrophy in atopic individuals; and jaw abnormalities in certain ethnic groups.

• Obesity and weight gain: Body mass index (BMI) >30 kg/m² is present in 60-90% of OSA patients, with OSA severity correlating with BMI. Excess soft tissue in the neck increases pharyngeal mass loading, lateral pharyngeal wall compression, and parapharyngeal fat deposition (visible on imaging). Obesity also reduces functional residual capacity, increases esophageal pressures, and alters respiratory system mechanics. Central obesity (visceral fat) may be particularly relevant. Even modest weight gain (5-10% of body weight) can worsen OSA severity, and weight loss of 10-15% can substantially improve OSA.

• Age and sex: OSA prevalence increases with age, particularly after age 40-50, due to decreased pharyngeal muscle tone with aging, changes in collagen composition of airway tissues, and decreased arousability threshold. Men are 2-4 times more likely to have OSA than premenopausal women, suggesting a protective effect of female hormones (particularly progesterone, which enhances respiratory drive and increases arousal threshold). Postmenopausal women have OSA prevalence approaching that of men, supporting hormonal influences.

• Craniofacial abnormalities: Skeletal Class II malocclusion (retrognathia/micrognathia), narrow palatal vault, reduced posterior airway space, and certain syndromic conditions (Down syndrome, Marfan syndrome, Ehlers-Danlos syndrome, acromegaly) significantly increase OSA risk. These conditions alter the mechanical forces acting on the airway.

• Nasal obstruction: Chronic rhinitis, allergic rhinitis, polyps, septal deviation, and turbinate hypertrophy increase airway resistance, requiring greater negative intrapharyngeal pressures for airflow. This increased resistance may trigger obstructive events and is particularly relevant in patients with baseline anatomic predisposition.

• Neuromuscular disorders: Myasthenia gravis, amyotrophic lateral sclerosis, Parkinson's disease, stroke, and spinal cord injury impair upper airway motor control and increase OSA risk through reduced pharyngeal tone and/or decreased arousal responsiveness.

• Medications and substances: Sedatives (benzodiazepines, barbiturates, non-benzodiazepine hypnotics), opioids, alcohol, and anticholinergics reduce arousal threshold and/or pharyngeal tone, worsening OSA. Alcohol consumption before sleep is particularly problematic.

• Acromegaly and endocrine disorders: Growth hormone excess increases soft tissue mass, mandibular prognathism, and tongue enlargement. Hypothyroidism causes myxedema of pharyngeal tissues and reduced ventilatory drive. Polycystic ovary syndrome increases risk in women through obesity and possibly hormonal mechanisms.

• Smoking: Active smoking increases pharyngeal inflammation and edema, and is associated with increased OSA risk.

• Excessive daytime somnolence (EDS): The hallmark symptom, characterized by irresistible urges to sleep during the day, unintentional napping, and difficulty maintaining wakefulness, results directly from sleep fragmentation and non-restorative sleep architecture. EDS impairs cognitive function, judgment, and driving ability, significantly increasing motor vehicle accident risk (5-7-fold increased relative risk). However, notably, some OSA patients—especially older individuals—may not report EDS despite severe OSA, a phenomenon termed "EDS dissociation" that limits the utility of subjective daytime sleepiness as a screening tool.

• Nocturnal witnessed apneas: Partners frequently report observing witnessed breathing pauses (apneas) lasting 20-120 seconds, often accompanied by gasping, snorting, or choking arousals. These observations are highly specific for OSA and should prompt diagnostic evaluation.

• Loud, habitual snoring: Non-apneic snoring results from vibration of the soft palate and oropharyngeal tissues during inspiration through a narrowed airway. While snoring is extremely common (20-40% of adults), loud habitual snoring, particularly when interrupted by apneic pauses, has high positive predictive value for OSA. Conversely, absence of snoring does not exclude OSA, particularly in thin patients or those with hypopnea-predominant disease.

• Nocturnal gasping, choking, or arousal: Patients report abrupt arousals with sensations of choking, gasping for breath, or sudden awakening in panic. These reflect severe hypoxemia or hypercapnia triggering arousal. Some patients describe waking with a dry mouth due to mouth breathing during sleep disruption.

• Nocturia and enuresis: Obstructive events may trigger arousals associated with sudden bladder contractions (triggered by arousal-mediated cholinergic activation and increased intrathoracic pressures), resulting in frequent nighttime urination (nocturia >2 times per night). Nocturia is a presenting complaint in 50% of OSA patients. Bedwetting (enuresis) in children with OSA results from sleep fragmentation disrupting normal enuresis suppression.

• Insomnia and sleep maintenance difficulty: Contrary to the popular conception that OSA causes hypersomnolence, some patients present with insomnia, reporting difficulty staying asleep, frequent arousals, and unrefreshing sleep. This may reflect lighter baseline sleep architecture or specific neurobiologic variability.

• Morning headaches: Occur in 10-30% of OSA patients, typically bilateral and described as pressure-like, and result from sleep-related hypercapnia (CO₂ retention during periods of hypoventilation) and potential increased intracranial pressure during events. Morning headaches improve with successful treatment.

• Personality changes and cognitive dysfunction: Memory impairment, decreased concentration, irritability, depression, and mood disturbance result from sleep fragmentation and daytime somnolence. Cognitive dysfunction is reversible with effective OSA treatment in most patients.

• Erectile dysfunction: Present in 25-90% of OSA patients depending on severity, results from sleep fragmentation, sympathetic hyperactivation, and endothelial dysfunction impairing nitric oxide-mediated vasodilation.

• Physical examination findings:
• Oropharyngeal anatomy: Increased Mallampati score (3-4 indicates palate obscured by enlarged tonsils), tonsillar hypertrophy (graded 1-4), adenoid hypertrophy, soft palate elongation, palatal vault narrowing, and lateral pharyngeal wall collapse during inspiration
• Craniofacial structure: Retrognathia (chin positioned posterior to lower lip), micrognathia (small mandible), maxillary hypoplasia, high-arched palate, and narrow palatal width
• Nasal examination: Septal deviation, polyps, turbinate hypertrophy, signs of chronic rhinitis
• Neck examination: Increased neck circumference (>40 cm in men, >37 cm in women predicts increased OSA risk), fatty infiltration, excessive soft tissue
• General: Obesity (BMI calculation), blood pressure elevation (hypertension present in 40-80% of OSA patients)

• Important clinical variants: Positional OSA (exclusively supine-related, accounting for 40-50% of patients) may be milder and more responsive to positional therapy; REM-related OSA (obstructive events concentrated in REM sleep) presents with less EDS; and central sleep apnea can coexist with obstructive events (complex sleep apnea), particularly when opioids or high-pressure CPAP is used.

• Clinical history and pre-test probability assessment: The STOP-BANG questionnaire (Snoring, Tiredness/daytime somnolence, Observed apnea, hyPertension, BMI >30, Age >50, Neck circumference >40 cm, male Gender) is a validated screening tool with sensitivity 83-93% and specificity 56-65% for moderate-to-severe OSA (AHI ≥15). Scoring ≥3 indicates increased risk. The Epworth Sleepiness Scale (ESS) (0-24 scale, with >10 suggesting EDS) quantifies subjective daytime somnolence but has poor sensitivity and specificity as a standalone diagnostic tool due to EDS dissociation. Clinical assessment should systematically evaluate witnessed apneas, snoring, sleep structure disruption, daytime symptoms, and cardiovascular risk factors.

• Polysomnography (PSG): The gold standard diagnostic test, PSG is an in-laboratory, attended study recording electroencephalography (EEG), electromyography (chin and anterior tibialis), electrooculography (EOG), electrocardiography (ECG), nasal pressure/thermistor airflow monitoring, thoracic and abdominal respiratory effort sensors, pulse oximetry (SpO₂), and leg movement sensors. PSG precisely quantifies sleep architecture, arousals, and oxygen desaturation, with superiority in detecting central sleep apnea and complex sleep apnea. However, PSG is labor-intensive, costly, and associated with first-night effect (reduced sleep and REM latency), potentially underestimating OSA severity.

• Home Sleep Apnea Testing (HSAT): Portable devices measuring 4-7 parameters (nasal airflow, respiratory effort, oxygen saturation, heart rate, and sometimes body position) allow remote testing. HSAT is more accessible, lower-cost, and reduces first-night effect. Sensitivity and specificity of HSAT for moderate-to-severe OSA (AHI ≥15) are 90

Immediate stabilization (uncommon but tested)

• Acute hypercapnic respiratory failure: patients with OSA plus obesity hypoventilation or opioid/sedative exposure may present somnolent and acidotic. Noninvasive ventilation (bilevel PAP) is the initial support; supplemental oxygen alone can blunt hypoxic drive, prolong apneas, and worsen CO\u2082 retention.
• Perioperative airway risk: OSA patients are exquisitely sensitive to opioids, benzodiazepines, and propofol; extubate awake, use regional/multimodal analgesia, and monitor with continuous oximetry per American Society of Anesthesiologists perioperative OSA recommendations.

First-line therapy

• Positive airway pressure: CPAP is first-line for all adults with moderate-to-severe OSA and for symptomatic mild OSA (American Academy of Sleep Medicine, 2019 PAP guideline). It works as a pneumatic splint, raising intraluminal pressure above the critical closing pressure. Auto-titrating PAP or BPAP is used for pressure intolerance or coexisting hypoventilation.
• Behavioral measures: weight loss (AASM/USPSTF-endorsed intensive behavioral counseling), avoidance of alcohol and sedative-hypnotics, and positional therapy for supine-predominant disease. These are adjuncts, never a substitute for PAP in severe disease.

Escalation / second-line

• Mandibular advancement oral appliances: for PAP-intolerant patients with mild-moderate OSA, custom devices fitted by a qualified dentist (AASM/American Academy of Dental Sleep Medicine).
• Wake-promoting agents (solriamfetol, modafinil, armodafinil, pitolisant): treat residual excessive sleepiness on adequate PAP; they do not treat obstruction.
• Incretin-based pharmacotherapy: tirzepatide is FDA-approved for moderate-to-severe OSA in adults with obesity, acting via weight reduction.

Surgical / definitive

• Adenotonsillectomy: first-line in children with OSA and adenotonsillar hypertrophy (American Academy of Pediatrics; AAO-HNS tonsillectomy guideline).
• Nasal surgery (septoplasty, turbinate reduction): improves PAP tolerance rather than curing OSA.
• Uvulopalatopharyngoplasty / expansion sphincter pharyngoplasty: for retropalatal collapse; success is partial, favored by low Friedman stage and large tonsils.
• Hypoglossal nerve stimulation: for select PAP-failure patients after drug-induced sleep endoscopy; contraindicated with complete concentric palatal collapse.
• Maxillomandibular advancement for skeletal deficiency; tracheostomy bypasses the obstruction entirely and is curative but reserved for refractory, life-threatening disease.

Complications of untreated OSA

• Systemic and resistant hypertension: nocturnal sympathetic surges and renin-angiotensin activation produce loss of nocturnal dipping; signaled by elevated overnight/early-morning pressures and blood pressure refractory to three agents. OSA is the most common identifiable cause of resistant hypertension (ACC/AHA hypertension guideline lists it among secondary causes).
• Atrial fibrillation: atrial stretch from markedly negative intrathoracic pressure plus autonomic surges; suggested by high AF recurrence after cardioversion or ablation in an untreated patient.
• Coronary disease, stroke, and nocturnal sudden cardiac death: endothelial dysfunction and prothrombotic state from intermittent hypoxia; OSA shifts sudden death toward the midnight-to-6 AM window, unlike the usual morning peak.
• Bradyarrhythmias and nocturnal heart block: vagal surge during apnea; sinus pauses seen on the polysomnogram ECG channel that resolve on PAP.
• Pulmonary hypertension and cor pulmonale: hypoxic vasoconstriction; look for elevated jugular venous pressure, peripheral edema, and right axis deviation. Obesity hypoventilation syndrome is signaled by daytime hypercapnia with an elevated serum bicarbonate.
• Metabolic and hepatic: insulin resistance and worsened metabolic dysfunction-associated steatotic liver disease.
• Motor vehicle collisions — an emergency of public safety; drowsy driving requires counseling and, in commercial drivers, reporting per state rules.
• Pediatric: failure to thrive, ADHD-like behavior, enuresis, and cor pulmonale.
• Ocular: floppy eyelid syndrome and nonarteritic anterior ischemic optic neuropathy.

Complications of treatment

• CPAP: nasal dryness/epistaxis, aerophagia, conjunctivitis from mask leak, skin breakdown, claustrophobia; treatment-emergent central sleep apnea appears as persistent central events on a well-titrated machine.
• Oral appliance: temporomandibular pain and permanent occlusal change.
• UPPP: velopharyngeal insufficiency (hypernasal speech, nasal regurgitation of liquids), nasopharyngeal stenosis, taste disturbance.
• Post-tonsillectomy hemorrhage is an airway emergency (peaks about a week postoperatively); post-adenotonsillectomy respiratory compromise in severe pediatric OSA warrants inpatient monitoring, and codeine carries an FDA boxed warning in this setting.

• Severity thresholds: AHI 5–14 mild, 15–29 moderate, ≥30 severe. Diagnosis requires AHI ≥5 with symptoms or cardiovascular comorbidity, or AHI ≥15 regardless of symptoms.
• Single best next step: a patient with snoring, witnessed apneas, and daytime sleepiness gets polysomnography (or home sleep apnea testing if uncomplicated, high pre-test probability, no significant cardiopulmonary disease). Do not jump to imaging, thyroid studies, or surgery first.
• The association examiners love: OSA and resistant hypertension / recurrent atrial fibrillation. Any obese, thick-necked patient whose blood pressure or AF will not stay controlled should be screened for OSA.
• Adults vs children: adults get CPAP first, whatever the anatomy; children with adenotonsillar hypertrophy get adenotonsillectomy first (AAP). Reversing this pairing is the classic trap.
• Common distractor — supplemental oxygen: it may improve the saturation nadir but does not relieve obstruction and can prolong apneas and worsen hypercapnia. Oxygen is never the answer for isolated OSA.
• Buzzword pairs: pneumatic splint = CPAP; velopharyngeal insufficiency with nasal regurgitation = post-UPPP; complete concentric collapse at the palate on drug-induced sleep endoscopy = disqualifies hypoglossal nerve stimulation; floppy eyelid syndrome = OSA until proven otherwise.
• Distinguish the mimics: daytime hypercapnia with elevated serum bicarbonate points to obesity hypoventilation syndrome, not simple OSA; Cheyne-Stokes crescendo–decrescendo breathing with heart failure or opioid use is central, not obstructive, sleep apnea — absent respiratory effort is the discriminator.
• Perioperative pearl: STOP-BANG ≥3 flags high risk; opioids, benzodiazepines, and unmonitored recovery are the setup for postoperative respiratory arrest.
• Curative option: tracheostomy bypasses the collapsible segment and is the only universally effective surgery — reserved for refractory, life-threatening disease.